Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Microenvironment | 3 | 2025 | 257 | 0.910 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2025 | 208 | 0.790 |
Why?
|
| Oncolytic Virotherapy | 3 | 2025 | 19 | 0.740 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 341 | 0.730 |
Why?
|
| Vesiculovirus | 1 | 2014 | 6 | 0.430 |
Why?
|
| Complement System Proteins | 1 | 2014 | 32 | 0.420 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 59 | 0.420 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2013 | 2 | 0.400 |
Why?
|
| Viremia | 1 | 2013 | 23 | 0.390 |
Why?
|
| Interferon-beta | 3 | 2013 | 33 | 0.390 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 93 | 0.380 |
Why?
|
| Interferon-alpha | 2 | 2008 | 52 | 0.290 |
Why?
|
| RNA Caps | 1 | 2007 | 5 | 0.280 |
Why?
|
| eIF-2 Kinase | 1 | 2007 | 11 | 0.280 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1429 | 0.260 |
Why?
|
| Protein Biosynthesis | 2 | 2008 | 267 | 0.250 |
Why?
|
| CTLA-4 Antigen | 1 | 2025 | 32 | 0.240 |
Why?
|
| Oncolytic Viruses | 1 | 2025 | 12 | 0.240 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 46 | 0.230 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 86 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 140 | 0.220 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1134 | 0.210 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 34 | 0.210 |
Why?
|
| Neutralization Tests | 2 | 2014 | 28 | 0.210 |
Why?
|
| Vero Cells | 2 | 2014 | 39 | 0.210 |
Why?
|
| Immunotherapy | 1 | 2025 | 251 | 0.210 |
Why?
|
| Animals | 6 | 2025 | 13485 | 0.210 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 85 | 0.200 |
Why?
|
| DNA Primers | 2 | 2014 | 204 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 208 | 0.180 |
Why?
|
| Mice | 3 | 2025 | 5899 | 0.170 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1483 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1888 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 41 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 3013 | 0.140 |
Why?
|
| Radiography | 1 | 2019 | 469 | 0.140 |
Why?
|
| Pneumonia | 1 | 2019 | 122 | 0.140 |
Why?
|
| Radiology | 1 | 2019 | 132 | 0.130 |
Why?
|
| Neoplasms | 1 | 2025 | 1314 | 0.120 |
Why?
|
| Viral Envelope Proteins | 1 | 2014 | 33 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2014 | 236 | 0.100 |
Why?
|
| Chromatography | 1 | 2013 | 11 | 0.100 |
Why?
|
| Humans | 6 | 2025 | 52441 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 182 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 485 | 0.090 |
Why?
|
| Cricetinae | 2 | 2008 | 189 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 475 | 0.080 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2008 | 1 | 0.070 |
Why?
|
| Encephalitis Virus, Eastern Equine | 1 | 2008 | 3 | 0.070 |
Why?
|
| Cell Line | 2 | 2008 | 1020 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2008 | 132 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 580 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 587 | 0.060 |
Why?
|
| Macrophages | 1 | 2008 | 357 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2025 | 24 | 0.060 |
Why?
|
| Immunomodulation | 1 | 2024 | 36 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2025 | 641 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2024 | 1724 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1045 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 521 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1576 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2433 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 3709 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 4046 | 0.020 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Encephalomyelitis, Equine | 1 | 2008 | 3 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 6713 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 164 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 656 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2008 | 357 | 0.020 |
Why?
|
| Child | 1 | 2019 | 7194 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2008 | 478 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1583 | 0.010 |
Why?
|
| Male | 1 | 2019 | 26874 | 0.010 |
Why?
|
| Female | 1 | 2019 | 28277 | 0.010 |
Why?
|